Asparaginase-Based Treatments in Young and Older Adults With Acute Lymphoblastic Leukemia: Leveraging the Pediatric Experience

Download this slideset from a live CCO symposium for an expert overview on applying pediatric ALL regimens to the treatment of AYA and adult patients with ALL.

Wendy Stock, MD
Program Director Released: December 15, 2021

Download this slideset from a live CCO symposium for an expert overview of considerations regarding the use of asparaginase in the treatment of ALL, including discussion of available formulations and optimal management of hypersensitivity reactions.

Stephen P. Hunger, MD Released: December 15, 2021

Download this slideset from a live CCO symposium for an expert overview on identifying and managing adverse events associated with asparaginase-based therapy in patients with ALL, including discussion of hepatotoxicity, thrombosis, pancreatitis, hypertriglyceridemia, and factors contributing to their development.

Wendy Stock, MD
Program Director Emily Curran, MD Dan Douer, MD Scott Howard, MD, MSc Stephen P. Hunger, MD Released: December 15, 2021

Download this short summary slideset of key takeaways from a live CCO Webinar on the optimal use of pediatric asparaginase-based regimens in the treatment of a AYA and adult patients with ALL.

Wendy Stock, MD
Program Director Emily Curran, MD Dan Douer, MD Scott Howard, MD, MSc Stephen P. Hunger, MD Released: December 20, 2021

Watch this on-demand webcast of a live CCO webinar where an expert panel discusses the optimal use of pediatric asparaginase regimens in the treatment of AYA and adult patients with ALL, including patient case discussions and practical guidance on strategies to support completion of therapy.

Wendy Stock, MD
Program Director Emily Curran, MD Dan Douer, MD Scott Howard, MD, MSc Stephen P. Hunger, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits™ Released: January 24, 2022 Expired: January 23, 2023